IBM

IBM Reveals Equity Compensation Details

International Business Machines Corporation (IBM) has filed its latest 10-K report with the SEC, revealing details about its equity compensation plans and ownership structure. The report indicates that as of December 31, 2023, IBM had a total of 39,041,651 outstanding equity securities, which included 9,259,638 options, 21,624,285 Restricted Stock Units (RSUs), and 5,239,655 Performance Share Units (PSUs) under equity compensation plans approved by security holders. Additionally, there were 2,918,073 outstanding equity securities under plans not approved by security holders.

The weighted-average exercise price of the outstanding options was $130.23, and the number of securities remaining available for future issuance under equity compensation plans was 50,331,632.

The report also highlights that in connection with 15 acquisition transactions, 356,373 additional share-based awards, consisting of stock options, were outstanding at the end of 2023 as a result of IBM’s assumption of awards granted by the acquired entities. The weighted-average exercise price of these awards was $24.43.

Furthermore, the report provides insights into the material features of each equity compensation plan, including the 2001 Long-Term Performance Plan, the PWCC Acquisition Long-Term Performance Plan, the IBM Red Hat Acquisition Long-Term Performance Plan, and the Amended and Restated Deferred Compensation and Equity Award Plan (DCEAP).

Following these announcements, the company's shares moved -0.9%, and are now trading at a price of $184.13. Check out the company's full 10-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS